Mary Wilson
Well-known member
March 3, 2023 / 72(9);232–243
http://dx.doi.org/10.15585/mmwr.mm7209a4
Agam K. Rao, MD[SUP]1[/SUP]; Caroline A. Schrodt, MD[SUP]1[/SUP]; Faisal S. Minhaj, PharmD[SUP]1[/SUP][SUP],2[/SUP]; Michelle A. Waltenburg, DVM[SUP]3[/SUP]; Shama Cash-Goldwasser, MD[SUP]2[/SUP]; Yon Yu, PharmD[SUP]4[/SUP]; Brett W. Petersen, MD[SUP]1[/SUP]; Christina Hutson, PhD[SUP]1[/SUP]; Inger K. Damon, MD, PhD[SUP]3[/SUP]
Summary
What is already known about this topic?
During the 2022 global monkeypox (mpox) outbreak, some patients have experienced severe clinical manifestations. Medical countermeasures (MCMs) developed to treat smallpox have been used to treat mpox.
What is added by this report?
Data relevant to the use of tecovirimat, brincidofovir, cidofovir, trifluridine ophthalmic solution, and vaccinia immune globulin intravenous were reviewed. Animal models, MCM use for human cases of related orthopoxviruses, unpublished data, input from clinician experts, and experience during CDC mpox consultations were also evaluated to develop interim clinical treatment considerations.
What are the implications for public health practice?
Until data from controlled studies are available, these interim clinical considerations facilitate strategic decision-making about the use of MCMs to manage specific severe manifestations of mpox.
https://www.cdc.gov/mmwr/volumes/72/wr/mm7209a4.htm?s_cid=mm7209a4_w
http://dx.doi.org/10.15585/mmwr.mm7209a4
Agam K. Rao, MD[SUP]1[/SUP]; Caroline A. Schrodt, MD[SUP]1[/SUP]; Faisal S. Minhaj, PharmD[SUP]1[/SUP][SUP],2[/SUP]; Michelle A. Waltenburg, DVM[SUP]3[/SUP]; Shama Cash-Goldwasser, MD[SUP]2[/SUP]; Yon Yu, PharmD[SUP]4[/SUP]; Brett W. Petersen, MD[SUP]1[/SUP]; Christina Hutson, PhD[SUP]1[/SUP]; Inger K. Damon, MD, PhD[SUP]3[/SUP]
Summary
What is already known about this topic?
During the 2022 global monkeypox (mpox) outbreak, some patients have experienced severe clinical manifestations. Medical countermeasures (MCMs) developed to treat smallpox have been used to treat mpox.
What is added by this report?
Data relevant to the use of tecovirimat, brincidofovir, cidofovir, trifluridine ophthalmic solution, and vaccinia immune globulin intravenous were reviewed. Animal models, MCM use for human cases of related orthopoxviruses, unpublished data, input from clinician experts, and experience during CDC mpox consultations were also evaluated to develop interim clinical treatment considerations.
What are the implications for public health practice?
Until data from controlled studies are available, these interim clinical considerations facilitate strategic decision-making about the use of MCMs to manage specific severe manifestations of mpox.
https://www.cdc.gov/mmwr/volumes/72/wr/mm7209a4.htm?s_cid=mm7209a4_w